首页> 外文期刊>Pediatric blood & cancer >Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years.
【24h】

Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years.

机译:儿童期外周血T细胞淋巴瘤:英国超过20年基于人群的经验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Peripheral T-cell lymphomas (PTCL) are very rare in children and this has prevented assessment of best treatment and prognosis. PROCEDURE: Registry-based experience in England, Scotland and Wales over a 20-year period was studied to address these shortfalls. Anaplastic large cell lymphoma and mycosis fungoides were excluded due to recent publications describing UK experience with these disorders. RESULTS: Twenty-five cases were identified, comprising 1.6% of non-Hodgkin lymphoma (NHL) registrations; 17 (68%) children with PTCL-unspecified (PTCL-u), 3 (12%) with angiocentric PTCL, 3 (12%) with angioimmunoblastic PTCL, and 2 (8%) with subcutaneous panniculitis-like T-cell lymphoma. Eighteen children were male, with a male/female ratio of 2.6:1. Median age was 7 (range 1-14) years. Eleven children (44%) died and actuarial survival was 76% at 1 year, 64% at 3 years and 59% at 5 years. Treatments given were subdivided between group T (regimens for T NHL or acute lymphoblastic leukaemia) or groupB (regimens for B NHL). Amongst the 17 children with PTCL-u, 9/12 children in group T survived compared with 1/5 group B. CONCLUSIONS: The Children's Cancer and Leukaemia Group recommendation that children with PTCL-u receive group T therapy is supported by this series. The numbers of children with other types of PTCL were too small to allow conclusions on best therapy.
机译:背景:周围型T细胞淋巴瘤(PTCL)在儿童中非常罕见,这妨碍了对最佳治疗方法和预后的评估。程序:研究了英格兰,苏格兰和威尔士20年来基于注册表的经验,以解决这些不足。由于最近的出版物描述了英国在这些疾病上的经验,因此排除了变性变性大细胞淋巴瘤和真菌病真菌。结果:确定了25例病例,占非霍奇金淋巴瘤(NHL)登记的1.6%。 17例(68%)儿童患有PTCL-unspecified(PTCL-u),3例(12%)患有以血管中心性PTCL,3例(12%)患有血管免疫母细胞PTCL,2例(8%)患有皮下脂膜炎样T细胞淋巴瘤。十八个孩子是男性,男女比例为2.6:1。中位年龄为7岁(范围1-14)。十一名儿童(占44%)死亡,精算生存率在1年时为76%,在3岁时为64%,在5岁时为59%。给予的治疗分为T组(T NHL或急性淋巴细胞白血病的治疗方案)或B组(B NHL的治疗方案)。在17例PTCL-u患儿中,T组9/12例患儿存活,而B组则为1/5。结论:儿童癌症和白血病小组建议PTCL-u患儿接受T组治疗。患有其他类型PTCL的儿童人数太少,无法得出最佳治疗的结论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号